强生公司完成以30亿美元收购Halda的交易预计调整后每股收益将受冲击

环球市场播报2025-12-29

强生公司（Johnson & Johnson）表示，已完成对Halda Therapeutics价值30.5亿美元的收购，并预计该交易将使其调整后每股收益减少20美分。　　强生公司上月披露该交易时表示，由于短期融资以及与Halda员工股权奖励相关的费用，该交易将使其2026年调整后每股收益减少约15美分。　　这家总部位于新泽西州新不伦瑞克的公司周一表示，由于该交易于2025年完成，预计第四财季...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2595735028?lang=zh_CN&edition=full","thumbnail":"https://n.sinaimg.cn/finance/transform/162/w550h412/20251229/9c3d-ac2a940e4f1d7c3382f93e20775bac3f.png","is_english":false,"pubTime":"2025-12-29 22:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2595735028","market":"us","top_or_hot":-1,"title":"强生公司完成以30亿美元收购Halda的交易 预计调整后每股收益将受冲击","media":"环球市场播报","content":"<div>\n<p>强生公司（Johnson & Johnson）表示，已完成对Halda Therapeutics价值30.5亿美元的收购，并预计该交易将使其调整后每股收益减少20美分。\n　　强生公司上月披露该交易时表示，由于短期融资以及与Halda员工股权奖励相关的费用，该交易将使其2026年调整后每股收益减少约15美分。\n　　这家总部位于新泽西州新不伦瑞克的公司周一表示，由于该交易于2025年完成，预计第四财季...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2025-12-29/doc-inhentrz7745727.shtml\">网页链接</a>\n\n</div>\n","source":"sina_us","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>强生公司完成以30亿美元收购Halda的交易 预计调整后每股收益将受冲击</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n强生公司完成以30亿美元收购Halda的交易 预计调整后每股收益将受冲击\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-29 22:32 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/usstock/c/2025-12-29/doc-inhentrz7745727.shtml><strong>环球市场播报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>强生公司（Johnson & Johnson）表示，已完成对Halda Therapeutics价值30.5亿美元的收购，并预计该交易将使其调整后每股收益减少20美分。\n　　强生公司上月披露该交易时表示，由于短期融资以及与Halda员工股权奖励相关的费用，该交易将使其2026年调整后每股收益减少约15美分。\n　　这家总部位于新泽西州新不伦瑞克的公司周一表示，由于该交易于2025年完成，预计第四财季...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/usstock/c/2025-12-29/doc-inhentrz7745727.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BZ1G4Q59.USD","symbol_name":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","start_time":0,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-12-29/doc-inhentrz7745727.shtml","article_id":"2595735028","we_media_id":null,"thumbnails":["https://n.sinaimg.cn/finance/transform/162/w550h412/20251229/9c3d-ac2a940e4f1d7c3382f93e20775bac3f.png"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2595735028","pubTimestamp":1767018768,"columns":[],"sourceInfo":{"source_id":"sina_us","name":"新浪美股"},"weMediaInfo":null,"summary":"强生公司表示，已完成对Halda Therapeutics价值30.5亿美元的收购，并预计该交易将使其调整后每股收益减少20美分。　　强生公司上月披露该交易时表示，由于短期融资以及与Halda员工股权奖励相关的费用，该交易将使其2026年调整后每股收益减少约15美分。　　这家总部位于新泽西州新不伦瑞克的公司周一表示，由于该交易于2025年完成，预计第四财季以及明年的调整后每股收益将受到影响。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2430703251.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (USD) INC","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","LU0124676726.USD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (USD) ACC","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","BK4534":"瑞士信贷持仓","LU1221951129.SGD":"NORDEA 1 STABLE RETURN \"HM\" (SGDHDG) INC","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","LU0683600562.USD":"AB SELECT US EQUITY \"A\" (USD) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","SG9999002232.USD":"Allianz Global High Payout USD","LU0787776722.HKD":"AB SELECT US EQUITY PORTFOLIO \"A\" (HKD) ACC","IE00BVYPNV92.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) ACC","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU0320765646.SGD":"FTIF - Franklin Income A MDIS SGD-H1","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","BK4592":"伊斯兰概念","LU2471134952.CNY":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (CNYHDG) INC","BK4504":"桥水持仓","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC","BK4568":"美国抗疫概念","BK4588":"碎股","BK4550":"红杉资本持仓","LU1244550494.USD":"FRANKLIN GLOBAL MULTI-ASSET INCOME \"A\" (USDHEDGED) ACC","LU2347655156.SGD":"JPMorgan Investment Funds - Global Income A (icdiv) SGD-H","LU0795875086.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD","LU2129689605.HKD":"FRANKLIN GLOBAL INCOME \"A\" (HKD) INC","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","LU2129689514.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) INC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1221951046.USD":"NORDEA 1 STABLE RETURN \"HM\" (USDHDG) INC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU2430703095.HKD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (HKD) INC","JNJ":"强生"},"translate_title":"Johnson & Johnson completes $3 billion deal to acquire Halda and expects hit to adjusted earnings per share","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":1.5},"content_text":"强生公司（Johnson & Johnson）表示，已完成对Halda Therapeutics价值30.5亿美元的收购，并预计该交易将使其调整后每股收益减少20美分。\n　　强生公司上月披露该交易时表示，由于短期融资以及与Halda员工股权奖励相关的费用，该交易将使其2026年调整后每股收益减少约15美分。\n　　这家总部位于新泽西州新不伦瑞克的公司周一表示，由于该交易于2025年完成，预计第四财季以及明年的调整后每股收益将受到影响。目前预计总影响约为每股20美分，由2025年和2026年平均分摊。\n　　强生公司表示，将在定于1月21日举行的第四财季财报电话会议上提供更多细节。\n　　这项对Halda的收购旨在加强这家医疗健康公司的肿瘤学在研产品线。通过此次收购，强生公司将Halda的主要候选药物HLD-0915纳入其产品组合，这是一种每日一次的前列腺癌疗法。\n　　该交易还增加了几个针对乳腺癌、肺癌和多种其他肿瘤类型的早期候选药物。\n　　“既然我们已经完成了这项收购，我们将专注于发掘这一前景广阔的新型候选产品管线的潜力，”创新药物和研发执行副总裁约翰．里德（John Reed）说。\n \n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：刘明亮","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2595735028","isCrawlerRequest":true}

强生公司完成以30亿美元收购Halda的交易 预计调整后每股收益将受冲击

精彩评论

强生公司完成以30亿美元收购Halda的交易预计调整后每股收益将受冲击